Thursday, September 14, 2017

4:00 - 6:00 p.m.  Registration

6:00 - 6:10 p.m.  Opening Ceremony and Welcome – Chicago Fairmont Hotel, Imperial Room
F.R. Hirsch, E. Vokes, J. Patel

6:10 - 7:30 p.m.  Keynote Addresses:

6:10 - 6:30 p.m.  Beyond approved PD-1/PD-L1 strategies: Biomarkers besides PD-L1 and IO combinations Likely to change practice in the near term
Hossein Borghaei

6:30 - 6:50 p.m.  On the edge: IO toxicity management and use in patients with underlying autoimmunity
Matthew Hellmann

6:50 - 7:10 p.m.  The interplay of IO and radiation therapy
Roy Decker

7:10 - 7:30 p.m.  Value Frameworks in Cancer Care: A Patient Perspective
Janet Freeman-Daily

7:30 - 9:00 p.m.  Dinner Symposium Sponsored by AstraZeneca
The Role of Immunotherapy for the Management of Patients with Locally Advanced NSCLC
Friday, September 15, 2017

7:00 a.m. - 5:00 p.m. Registration

8:00 - 9:00 a.m. Breakfast Symposium Sponsored by AstraZeneca

8:00 - 9:00 a.m. Breakfast in the registration area

9:00 - 9:05 a.m. Welcome
Location: Imperial Room

Chairs: Fred Hirsch, Heather Wakelee

9:05 - 9:20 a.m. Research and Policy Priorities in Tobacco Control
Stephanie Land

9:20 - 9:35 a.m. Barriers to Widespread Lung Cancer Screening
James Mulshine

9:35 - 9:50 a.m. Pulmonologists in the Era of Precision Oncology
Colin Gillespie

9:50 - 10:05 a.m. Optimal tissue utilization in the molecular and IO era
Jeremy Segal

10:05 - 10:20 a.m. Blood-based Biomarkers in Thoracic Oncology
Max Diehn

10:20 - 10:35 a.m. Access to care, cost, and health disparities—shifting sands
Robert Winn

10:35 - 11:05 a.m. Oligometastatic disease and synchronous primaries – optimal approaches
Puneeth Iyengar
Osman Ahmed
Jessica Donington

11:05 - 11:30 a.m. Break

11:30 a.m. - 1:00 p.m. Highlighted Oral Session 1
Location: Imperial Room
Session Chairs: Mary Jo Fidler & Jyoti Patel

11:30 - 11:55 a.m. How BAPI Modulates Gene-Environment Interaction In Carcinogenesis and Renders Tumor Cells Resistant to Chemotherapy
Michele Carbone

11:55 a.m. - 12:03 p.m. OA01.02 Novel Use of an Electronic Medical Record to Monitor Performance of a Lung Cancer Screening Program
Cherie Erkmen

12:03 - 12:11 p.m. OA01.03 Attrition Rate in Community-Based Lung Cancer Screening: One and Done
Alexander Carlson
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| 12:11 - 12:19 p.m. | **OA01.04**  
A Comparability Study Verifying the Analytic  
Performance of a Blood-based Gene Expression  
Classifier to Identify Benign Pulmonary Nodules | Lyssa Friedman          |
| 12:19 - 12:26 p.m. | **Discussant abstracts OA01.02, OA01.03, OA01.04:** | Joy Feliciano           |
| 12:26 - 12:34 p.m. | **OA01.05**  
Radiation Dose and Fractionation for Limited-Stage  
Small Cell Lung Cancer: A Survey of US Radiation  
Oncologists on Practices | Matthew Farrell          |
| 12:34 - 12:50 p.m. | **Discussant abstract OA01.05** | Steven Chmura           |
| 1:00 - 2:30 p.m.   | **Lunch Symposia Sponsored by Takeda** |                         |
| 1:00 - 2:30 p.m.   | **Lunch in the registration area** |                         |
| 2:30 - 3:15 p.m.   | **Education Session 1A & 1B** |                         |
| 2:30 - 3:15 p.m.   | **Breakout Session 1A: Thoracic surgery at the “cutting edge”**  
Location: Imperial Room  
Chair: Malcolm DeCamp |                         |
| 2:30 - 2:40 p.m.   | Multiple lung nodules and GGOs—When to cut?                 | Malcolm DeCamp          |
| 2:40 - 2:50 p.m.   | Staging updates invasive vs radiographic                     | Linda Martin            |
| 2:50 - 3:00 p.m.   | Complex resection in pleural diseases (mesothelioma/thymic)    | Linda Martin            |
| 3:00 - 3:15 p.m.   | **Discussion**                                               |                         |
| 2:30 - 3:15 p.m.   | **Breakout Session 1B: Collateral damage in a new era of lung cancer treatment**  
Location: Gold Room  
Chair: Ken Rosenzweig |                         |
<p>| 2:30 - 2:40 p.m.   | Cardio-oncology issues                                     | Cliff Robinson          |
| 2:40 - 2:50 p.m.   | Toxicity concerns with targeted and novel therapies          | Ken Rosenzweig          |
| 2:50 - 3:00 p.m.   | Protons for thoracic indications to reduce toxicity          | Jim Urbanic             |
| 3:00 - 3:15 p.m.   | <strong>Discussion</strong>                                               |                         |
| 3:15 - 4:00 p.m.   | <strong>Education Session 2A &amp; 2B</strong>                               |                         |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chair</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 - 4:00 p.m.</td>
<td>Breakout Session 2A: Team Based Care in Oncology</td>
<td>Imperial Room</td>
<td>Kavitha Ramchandran</td>
<td>David Gerber</td>
</tr>
<tr>
<td>3:15 - 3:25 p.m.</td>
<td>Challenges and Opportunities of Team Based Care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:25 - 3:35 p.m.</td>
<td>Symptom Management Partnerships</td>
<td></td>
<td>Kavitha Ramchandran</td>
<td>Alison Tisch</td>
</tr>
<tr>
<td>3:25 - 3:45 p.m.</td>
<td>Shared Goal Setting for Elderly Patients with Lung Cancer</td>
<td></td>
<td>Monica Malec</td>
<td></td>
</tr>
<tr>
<td>3:45 - 4:00 p.m.</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 - 4:00 p.m.</td>
<td>Breakout Session 2B: In the Perioperative Setting</td>
<td>Gold Room</td>
<td>Jamie Chaft</td>
<td></td>
</tr>
<tr>
<td>3:15 - 3:25 p.m.</td>
<td>Neoadjuvant/Adjuvant Updates</td>
<td></td>
<td>Jamie Chaft</td>
<td></td>
</tr>
<tr>
<td>3:25 - 3:35 p.m.</td>
<td>Importance of Lymph node sampling</td>
<td></td>
<td>Ray Osarogiagbon</td>
<td></td>
</tr>
<tr>
<td>3:35 - 3:45 p.m.</td>
<td>Surveillance imaging</td>
<td></td>
<td>Leah Backhus</td>
<td></td>
</tr>
<tr>
<td>3:45 - 4:00 p.m.</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 - 4:30 p.m.</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 - 4:58 p.m.</td>
<td>Education Session 3A &amp; 3B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 - 4:58 p.m.</td>
<td>Session 3A</td>
<td>Imperial Room</td>
<td>Larry Feldman</td>
<td></td>
</tr>
<tr>
<td>4:30 - 4:38 p.m.</td>
<td>3A.01</td>
<td></td>
<td>Aparna Hegde</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti-PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:38 - 4:46 p.m.</td>
<td>3A.02</td>
<td></td>
<td>Stephen Chun</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Major Drivers of Combined Modality Therapy for Limited-Stage Small Cell Lung Cancer in the United States National Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:46 - 4:58 p.m.</td>
<td>Discussant abstracts 3A.01, 3A.02</td>
<td></td>
<td>Larry Feldman</td>
<td></td>
</tr>
<tr>
<td>4:30 - 4:58 p.m.</td>
<td>Session 3B</td>
<td>Gold Room</td>
<td>Tim Kruser</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Tim Kruser</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Location: Gold Room</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
4:30 - 4:38 p.m. 3B.01
Hematologic Malignancies in Lung Cancer Survivors – the Contribution of Radiation Therapy
Sarit Appel

4:38 - 4:58 p.m. Discussant abstract 3B.01
Tim Kruser

5:05 - 5:45 p.m. Education Session 4A & 4B

5:05 - 5:45 p.m. Session 4A
Location: Imperial Room
Chair: Fred Hirsch

5:05 - 5:13 p.m. 4A.02
Confirmation of Pathological Diagnosis in Lung Cancer Patients by ctDNA Detection through Ultra-Deep Sequencing
Geng Tian

5:13 - 5:21 p.m. 4A.03
Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1)
Abdul Rafeh Naqash

5:21 - 5:45 p.m. Discussant abstracts 4A.02, 4A.03
Fred Hirsch

5:05 - 5:45 p.m. Session 4B
Location: Gold Room
Chair: Ray Osarogiagbon

5:05 - 5:13 p.m. 4B.01
Lung Cancer Patients Migrate to Seek Better Care
Danh Pham

5:13 - 5:21 p.m. 4B.02
Increasing Survival in Stage IV NSCLC in Academic Versus Community Based Centers in the National Cancer Database
Sendhilnathan Ramalingam

5:21 - 5:29 p.m. 4B.03
Prospective Evaluation of Multidisciplinary Lung Cancer Care: Timeliness, Thoroughness, and Patient/Caregiver Perspectives
Matthew Smeltzer

5:29 - 5:45 p.m. Discussant abstracts 4B.01, 4B.02, 4B.03
Ray Osarogiagbon

5:50 - 6:35 p.m. Highlighted Oral Abstract Session 2
Location: Imperial Room
Chairs: Nisha Mohindra & Philip Bonomi

5:50 - 5:58 p.m. OA02.01
Comparison of iRECIST to RECIST1.1 for Following Response to Anti-PD1 Therapy in Patients with Non-Small Cell Lung Cancer
Sharyn Katz
5:58 - 6:06 p.m.  
**OA02.02**  
Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer  
Anna Chalmers

6:06 - 6:14 p.m.  
**OA02.03**  
Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial.  
Shahid Ahmed

6:14 - 6:26 p.m.  
**OA02.04**  
The Cost and the Benefit: Front-Line Immunotherapy For Non-Small Cell Lung Cancer  
Christine Bestvina

6:26 - 6:35 p.m.  
**Discussant abstracts OA02.01, OA02.02, OA02.03, OA02.04**  
Hossein Borghaei

6:35 - 7:30 p.m.  
**Poster Viewing and Reception**

7:30 - 9:30 p.m.  
**Dinner Symposium Sponsored by Bristol-Meyers Squibb, Genentech, Inc. and Merck & Co., Inc.**  
Location: Gold Room

7:30 - 9:30 p.m.  
**Dinner Symposium Sponsored by AstraZeneca**  
Location: Imperial Room
Saturday, September 16, 2017

7:00 a.m. - 1:00 p.m.  Registration

6:30 - 8:00 a.m.  Breakfast Symposium Sponsored by AstraZeneca – New Options and Evolving Strategies for Hitting the Target in EGFR-Mutant NSCLC

7:00 - 8:00 a.m.  Breakfast in the registration area

8:00 - 8:45 a.m.  Tumor Board

Faculty: Jeff Mueller, Jessica Donington, Tim Kruser, Doug Arenberg, Tom Hensing, Heather Wakelee

Moderated by Tim Murgu

8:45 - 10:15 a.m.  Highlighted Oral Session 3

Imperial Room

Chairs: Tom Hensing & Matt Steliga

8:45 - 8:53 a.m.  OA03.01  Andrew Nagy

Outcomes of Integrating Smoking Cessation Counseling in a Lung Cancer Screening Program

8:53 - 9:01 a.m.  OA03.02  Paul Walker

An Intervention Study to Reduce Black-White Treatment Disparities in Early Stage Non-Small Cell Lung Cancer

9:01 - 9:09 a.m.  OA03.03  Bretta McCall

Community Network Lung Cancer Screening Experience Underrepresents Medically Underserved and Geographically Remote Individuals

9:09 - 9:21 a.m.  Discussant abstracts OA03.01, OA03.02, OA03.03  Matthew Steliga

9:21 - 9:29 a.m.  OA03.04  Christopher Strouse

Radiation Therapy Before Anti-PD1 Therapy Not Associated with Survival Difference; Single Institution Retrospective Review

9:29 - 9:37 a.m.  OA03.05  Aparna Hegde

Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis

9:37 - 9:49 a.m.  Discussant abstracts OA03.04, OA03.05  Heather Wakelee
9:49 - 10:01 a.m.    OA03.06                Jose Barrueco
Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma

10:01 - 10:09 a.m.    OA03.07                Medha Sasane
Dabrafenib and Trametinib Combination Therapy versus Docetaxel in Previously Treated Metastatic NSCLC: An Adjusted Indirect Comparison

10:09 - 10:17 a.m.    OA03.08                Leora Horn
Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI)

10:17 - 10:30 a.m.    Discussant abstracts OA03.06, OA03.07, OA03.08   Tom Stinchcombe

10:30 - 10:45 a.m.    Break

10:45 - 12:00 p.m.    Year in Review  
Session chair: Everett Vokes

10:45 - 11:00 a.m.    Beyond EGFR and ALK    Mary Jo Fidler

11:00 - 11:15 a.m.    Staging Updates – AJCC updates    Sanja Dacic

11:15 - 11:30 a.m.    Debate: Patients with EGFR mutation NSCLC should postpone brain radiation for brain metastasis

11:15 - 11:22 a.m.    Pro: Lecia Sequist
11:22 - 11:29 a.m.    Con: Laurie Gaspar

11:30 - 11:45 a.m.    Debate: All patients with NSCLC Should Receive Immunotherapy 1st Line

11:30 - 11:37 a.m.    Pro: Jyoti Patel
11:37 - 11:44 a.m.    Con: John Heymach

11:45 a.m. - noon    Stage III NSCLC-current status, next steps    Everett Vokes